{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:02:22Z","timestamp":1784739742141,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.amjmed.2026.03.040","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:24:29Z","timestamp":1775150669000},"page":"1118-1127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antithrombotic strategies for the secondary prevention of stroke: A review"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6850-0525","authenticated-orcid":false,"given":"Forough","family":"Yazdanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano A.","family":"Sposato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.amjmed.2026.03.040_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.0054","article-title":"Short-term and long-term risk of recurrent vascular event by cause after ischemic stroke in young adults","volume":"7","author":"Verburgt","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.amjmed.2026.03.040_bib0002","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jacc.2019.06.039","article-title":"Antithrombotic therapy to prevent recurrent strokes in ischemic cerebrovascular disease","volume":"74","author":"Del Brutto","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.amjmed.2026.03.040_bib0003","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of Stroke in patients with Stroke and transient ischemic attack: a Guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.amjmed.2026.03.040_bib0004","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/svn-2020-000737","article-title":"Cilostazol for secondary stroke prevention: systematic review and meta-analysis","volume":"6","author":"Tan","year":"2021","journal-title":"Stroke Vasc Neurol"},{"issue":"3","key":"10.1016\/j.amjmed.2026.03.040_bib0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1052-3057(10)80176-4","article-title":"Preliminary experience using ticlopidine in clinical practice","volume":"4","author":"Gomez","year":"1994","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"1","key":"10.1016\/j.amjmed.2026.03.040_bib0006","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s12883-021-02341-2","article-title":"Antiplatelet drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis","volume":"21","author":"Del Giovane","year":"2021","journal-title":"BMC Neurol"},{"issue":"1\u20132","key":"10.1016\/j.amjmed.2026.03.040_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke","volume":"143","author":"Diener","year":"1996","journal-title":"J Neurol Sci"},{"issue":"1","key":"10.1016\/j.amjmed.2026.03.040_bib0008","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"9038","key":"10.1016\/j.amjmed.2026.03.040_bib0009","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","year":"1996","journal-title":"Lancet Lond Engl"},{"issue":"1","key":"10.1016\/j.amjmed.2026.03.040_bib0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12872-025-04668-x","article-title":"Comparison of P2Y12 inhibitors and aspirin in secondary prevention of coronary events: a meta-analysis of RCTs","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"10.1016\/j.amjmed.2026.03.040_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105581","article-title":"Cilostazol versus aspirin for secondary stroke prevention: systematic review and meta-analysis","volume":"30","author":"Lin","year":"2021","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"26","key":"10.1016\/j.amjmed.2026.03.040_bib0012","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2309137","article-title":"Dual antiplatelet treatment up to 72 hours after ischemic stroke","volume":"389","author":"Gao","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.amjmed.2026.03.040_bib0013","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2026.03.040_bib0014","article-title":"Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial","volume":"365","author":"Wang","year":"2019","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.amjmed.2026.03.040_bib0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and Aspirin or Aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N Engl J Med"},{"issue":"9431","key":"10.1016\/j.amjmed.2026.03.040_bib0016","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"10.1016\/j.amjmed.2026.03.040_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105464","article-title":"CYP2C19 Loss-of-function is associated with increased risk of ischemic stroke after transient ischemic attack in intracranial atherosclerotic disease","volume":"30","author":"Patel","year":"2021","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"27","key":"10.1016\/j.amjmed.2026.03.040_bib0018","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1056\/NEJMoa2111749","article-title":"Ticagrelor versus Clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA","volume":"385","author":"Wang","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amjmed.2026.03.040_bib0019","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jamaneurol.2019.2531","volume":"76","author":"Pan","year":"2019","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.amjmed.2026.03.040_bib0020","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/17474930231156753","article-title":"A systematic review and synthesis of global stroke guidelines on behalf of the World Stroke Organization","volume":"18","author":"Mead","year":"2023","journal-title":"Int J Stroke"},{"issue":"13","key":"10.1016\/j.amjmed.2026.03.040_bib0021","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa043033","article-title":"Comparison of Warfarin and Aspirin for symptomatic intracranial arterial stenosis","volume":"352","author":"Chimowitz","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amjmed.2026.03.040_bib0022","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1105335","article-title":"Stenting versus aggressive medical therapy for intracranial arterial stenosis","volume":"365","author":"Chimowitz","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.amjmed.2026.03.040_bib0023","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1161\/CIRCULATIONAHA.118.035864","article-title":"Stroke outcomes in the COMPASS trial","volume":"139","author":"Sharma","year":"2019","journal-title":"Circulation"},{"issue":"6 Suppl","key":"10.1016\/j.amjmed.2026.03.040_bib0024","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: american College of Chest Physicians evidence-based clinical practice guidelines (8th Edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.amjmed.2026.03.040_bib0025","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/clc.22572","volume":"39","author":"Cannon","year":"2016","journal-title":"Clin Cardiol"},{"issue":"9921","key":"10.1016\/j.amjmed.2026.03.040_bib0026","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.amjmed.2026.03.040_bib0027","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2024.08.011","article-title":"Milvexian versus apixaban for stroke prevention in atrial fibrillation: the LIBREXIA atrial fibrillation trial rationale and design","volume":"277","author":"Jain","year":"2024","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.amjmed.2026.03.040_bib0028","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1474-4422(15)70027-X","article-title":"Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis","volume":"14","author":"Sposato","year":"2015","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.amjmed.2026.03.040_bib0029","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.amjmed.2026.03.040_bib0030","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.amjmed.2026.03.040_bib0031","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amjmed.2026.03.040_bib0032","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2026.03.040_bib0033","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ahj.2021.12.017","article-title":"Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: a comprehensive analysis of high-risk subgroups","volume":"247","author":"Gencer","year":"2022","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.amjmed.2026.03.040_bib0034","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus Apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2026.03.040_bib0035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus Rivaroxaban in patients with atrial fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amjmed.2026.03.040_bib0036","first-page":"1847","article-title":"The 2020 Canadian Cardiovascular Society\/Canadian Heart Rhythm Society Comprehensive Guidelines for the management of atrial fibrillation","volume":"36","author":"Andrade","year":"2020","journal-title":"Can J Cardiol"},{"issue":"36","key":"10.1016\/j.amjmed.2026.03.040_bib0037","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.amjmed.2026.03.040_bib0038","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.amjmed.2026.03.040_bib0039","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1161\/STROKEAHA.120.031237","article-title":"Dabigatran or Aspirin after embolic stroke of undetermined source in patients with patent foramen Ovale: results from RE-SPECT ESUS","volume":"52","author":"Diener","year":"2021","journal-title":"Stroke"},{"issue":"23","key":"10.1016\/j.amjmed.2026.03.040_bib0040","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","article-title":"Rivaroxaban for stroke prevention after embolic stroke of undetermined source","volume":"378","author":"Hart","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2026.03.040_bib0041","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300235","article-title":"Apixaban versus Aspirin for embolic stroke of undetermined source","volume":"3","author":"Geisler","year":"2023","journal-title":"NEJM Evid"},{"issue":"7","key":"10.1016\/j.amjmed.2026.03.040_bib0042","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2023.27188","article-title":"Apixaban to prevent recurrence after cryptogenic stroke in patients with atrial cardiopathy: the ARCADIA randomized clinical trial","volume":"331","author":"Kamel","year":"2024","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.amjmed.2026.03.040_bib0043","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/clc.23647","article-title":"antagonist oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with previous stroke or intracranial hemorrhage: A systematic review and meta-analysis of observational studies","volume":"44","author":"Guo","year":"2021","journal-title":"Clin Cardiol"},{"issue":"12","key":"10.1016\/j.amjmed.2026.03.040_bib0044","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.49017","article-title":"Risk of intracranial hemorrhage associated with direct oral anticoagulation versus antiplatelet therapy: a systematic review and meta-analysis","volume":"7","author":"Coyle","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"14","key":"10.1016\/j.amjmed.2026.03.040_bib0045","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.122.060666","article-title":"Early versus delayed non-vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation (TIMING): A registry-based randomized controlled noninferiority study","volume":"146","author":"Oldgren","year":"2022","journal-title":"Circulation"},{"issue":"26","key":"10.1016\/j.amjmed.2026.03.040_bib0046","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2303048","article-title":"Early versus later anticoagulation for stroke with atrial fibrillation","volume":"388","author":"Fischer","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2026.03.040_bib0047","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1177\/23969873241251931","article-title":"Timing of oral anticoagulants initiation for atrial fibrillation after acute ischemic stroke: a systematic review and meta-analysis","volume":"9","author":"Palaiodimou","year":"2024","journal-title":"Eur Stroke J"},{"issue":"4","key":"10.1016\/j.amjmed.2026.03.040_bib0048","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/17474930241312649","article-title":"Ischemic stroke prevention in patients with atrial fibrillation and a recent ischemic stroke, TIA, or intracranial hemorrhage: a World Stroke Organization (WSO) scientific statement","volume":"20","author":"Sposato","year":"2025","journal-title":"Int J Stroke"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326002639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326002639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T16:15:30Z","timestamp":1784736930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934326002639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0002934326002639"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.03.040","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic strategies for the secondary prevention of stroke: A review","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.03.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}